Evommune, Inc.

EVMN NYSE CIK: 0002044725

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 1841 PAGE MILL RD, PALO ALTO, CA, 94304
Mailing Address 1841 PAGE MILL RD, PALO ALTO, CA, 94304
Phone (650) 223-7745
Fiscal Year End 1231
EIN 850742575

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events March 5, 2026 View on SEC
10-K Annual financial report March 5, 2026 View on SEC
4 Insider stock transaction report February 19, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment February 19, 2026 View on SEC
4 Insider stock transaction report February 18, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment February 17, 2026 View on SEC
4 Insider stock transaction report February 17, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 13, 2026 View on SEC
8-K Current report of material events February 13, 2026 View on SEC
8-K Current report of material events February 10, 2026 View on SEC

IPO Filings

S-1 October 9, 2025
  • Targeting a $90 billion market for chronic inflammation diseases with two mid-stage drugs (EVO756 and EVO301) aiming to address root causes.
  • Experienced leadership team with prior FDA approval success and board members involved in successful IPOs.
View Analysis

Annual Reports

10-K March 5, 2026
  • Successfully completed its Initial Public Offering (IPO) in November 2025, raising $157.3 million and listing on the NYSE.
  • Significantly strengthened financial position with $220.8 million raised from financing activities, resulting in a cash runway of approximately 34 months.
View Analysis

Insider Trading

BUY 1 insiders 1 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.